Theravance Biopharma, Inc. (TBPH)
NASDAQ: TBPH · Real-Time Price · USD
13.80
-0.12 (-0.83%)
At close: Aug 25, 2025, 4:00 PM
13.80
+0.01 (0.04%)
After-hours: Aug 25, 2025, 4:19 PM EDT
Theravance Biopharma Employees
Theravance Biopharma had 97 employees as of December 31, 2024. The number of employees decreased by 2 or -2.02% compared to the previous year.
Employees
97
Change (1Y)
-2
Growth (1Y)
-2.02%
Revenue / Employee
$795,928
Profits / Employee
$134,340
Market Cap
694.73M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 97 | -2 | -2.02% |
| Dec 31, 2023 | 99 | -12 | -10.81% |
| Dec 31, 2022 | 111 | -48 | -30.19% |
| Dec 31, 2021 | 159 | -200 | -55.71% |
| Dec 31, 2020 | 359 | 43 | 13.61% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
TBPH News
- 16 hours ago - Theravance Biopharma Completes Enrollment in Pivotal Phase 3 CYPRESS Study of Ampreloxetine in Patients with Symptomatic Neurogenic Orthostatic Hypotension due to Multiple System Atrophy - PRNewsWire
- 13 days ago - Theravance Biopharma, Inc. (TBPH) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 13 days ago - Theravance Biopharma, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update - PRNewsWire
- 4 weeks ago - Theravance Biopharma to Report Second Quarter 2025 Financial Results on August 12, 2025 - PRNewsWire
- 4 weeks ago - Theravance Biopharma to Participate in an Upcoming Investor Conference - PRNewsWire
- 2 months ago - Theravance Biopharma Announces Approval of YUPELRI® (revefenacin) by China's NMPA - PRNewsWire
- 3 months ago - Theravance Biopharma, Inc. Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 Million - PRNewsWire
- 3 months ago - Theravance Biopharma, Inc. (TBPH) Q1 2025 Earnings Call Transcript - Seeking Alpha